

1806



Docket No. 2026-4124US1

PATENT

#1  
B. Denny  
8/27/96

**UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Kawakami et al. Group Art Unit: 1806  
Serial No. : 08/417,174 Examiner: S. Huff  
Filed : April 5, 1995  
For : MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC  
AND THERAPEUTIC METHODS

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO RESTRICTION REQUIREMENT**

96 AUG 14 AM 8:48  
GROUP 180

Sir:

In response to the Restriction Requirement of July 3, 1996, Applicants elect the subject matter of claims 15-26 drawn to peptides of gp100, classified in Class 530, subclass 328. Applicants, however, traverse this Restriction Requirement for the reasons discussed below. Applicants were given until August 2, 1996 to respond to the Restriction Requirement. Hence this response is timely filed.

**REMARKS**

The present invention relates to nucleic acids, proteins and immunogenic peptides encoding melanoma antigens. The invention also relates to therapeutic and diagnostic uses of said nucleic acid sequences, proteins and peptides. Claims 1-14 are drawn to peptides of MART-1, classified in Class 530, Subclasses 328 and 350+ (Group I).